| While oncology companies are a
significant part of our coverage, Sonus represents our first coverage of chemotherapy
companies. Their lead product, TOCOSOL paclitaxel reduces the side effects of the
best-selling chemotherapy drug while increasing efficacy. We think the company story is compelling. This NIBM
Newsletter issue contains brand new information about the company's regulatory
plans and detailed efficacy and comparison data between TOCOSOL paclitaxel, Taxol,
Taxotere, and generic paclitaxel from our review of hundreds of pages of journal articles,
abstracts, and presentation posters. |
 |
|
